PetIQ Inc (NASDAQ:PETQ) – Investment analysts at William Blair upped their FY2018 EPS estimates for PetIQ in a research report issued to clients and investors on Wednesday, May 16th. William Blair analyst J. Andersen now anticipates that the company will earn $0.82 per share for the year, up from their previous estimate of $0.68.
PetIQ (NASDAQ:PETQ) last announced its earnings results on Tuesday, May 15th. The company reported $0.09 EPS for the quarter, topping the Zacks’ consensus estimate of $0.05 by $0.04. The firm had revenue of $115.10 million during the quarter, compared to analysts’ expectations of $108.54 million. PetIQ had a return on equity of 11.39% and a net margin of 0.17%. The business’s revenue for the quarter was up 71.8% on a year-over-year basis.
A number of other research firms have also recently issued reports on PETQ. BidaskClub upgraded PetIQ from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Zacks Investment Research upgraded PetIQ from a “hold” rating to a “buy” rating and set a $28.00 price objective for the company in a report on Friday, March 16th. Finally, Jefferies Group restated a “buy” rating and set a $31.00 price objective on shares of PetIQ in a report on Wednesday, April 11th. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $28.00.
Shares of PetIQ stock opened at $18.17 on Friday. The company has a market capitalization of $474.85 million and a PE ratio of 46.59. The company has a debt-to-equity ratio of 0.69, a current ratio of 2.35 and a quick ratio of 3.56. PetIQ has a one year low of $17.03 and a one year high of $28.23.
In related news, CEO Mccord Christensen sold 20,000 shares of the business’s stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $26.22, for a total transaction of $524,400.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO John Newland sold 5,500 shares of the business’s stock in a transaction on Monday, March 19th. The shares were sold at an average price of $24.83, for a total value of $136,565.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,500 shares of company stock valued at $1,657,765. 45.26% of the stock is owned by company insiders.
Several hedge funds have recently modified their holdings of the business. The Manufacturers Life Insurance Company lifted its holdings in shares of PetIQ by 64.0% in the 1st quarter. The Manufacturers Life Insurance Company now owns 6,838 shares of the company’s stock worth $182,000 after buying an additional 2,669 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in shares of PetIQ by 9.1% in the 4th quarter. TIAA CREF Investment Management LLC now owns 37,750 shares of the company’s stock worth $824,000 after buying an additional 3,152 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in shares of PetIQ by 29.1% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 16,400 shares of the company’s stock worth $437,000 after buying an additional 3,700 shares during the period. Keeler Thomas Management LLC purchased a new stake in shares of PetIQ in the 4th quarter worth $131,000. Finally, Wells Fargo & Company MN purchased a new stake in shares of PetIQ in the 3rd quarter worth $204,000. Institutional investors and hedge funds own 39.35% of the company’s stock.
PetIQ, Inc develops, manufactures, and distributes pet medications, and health and wellness products for dogs and cats in the United States, Canada, and Europe. It offers pet prescription medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars; and health and wellness products consisting of specialty treats and other pet products, which include dental treats and nutritional supplements.
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.